Phase I Evaluation of Sequential Doxorubicin Gemcitabine Then Ifosfamide Paclitaxel Cisplatin for Patients With Unresectable or Metastatic Transitional-Cell Carcinoma of the Urothelial Tract
Citations
243 citations
Cites methods from "Phase I Evaluation of Sequential Do..."
...HCl), triethylamine (Et3N), cathepsin B, ethylenediaminetetraacetic acid (EDTA) and reduced glutathione (GSH) were obtained from Fluka....
[...]
...In the second step, this precursor was mixed with doxorubicin (0.045 g; 7.75 10 5 mol) in DMSO (3.5 ml), and Et3N (30 ml) was added in three portions....
[...]
...P-Dox; poly(HPMA-co-MA-GFLGdoxorubicin; also known as PK1)) was synthesized by conjugating doxorubicin to poly(HPMA-co-MA-GFLG-ONp) in DMSO, in the presence of Et3N [18,24,26]....
[...]
...The conjugate carrying only doxorubicin (i.e. P-Dox; poly(HPMA-co-MA-GFLGdoxorubicin; also known as PK1)) was synthesized by conjugating doxorubicin to poly(HPMA-co-MA-GFLG-ONp) in DMSO, in the presence of Et3N [18,24,26]....
[...]
...All agents were applied once weekly for three weeks, rst, the monomers HPMA (1), MA-GFLG-TT (2) and MA-TyrNH2 (3) were copolymerized ecursor (4) in pyridine, yielding a copolymer containing besides gemcitabine several active groups in DMSO, in the presence of Et3N....
[...]
167 citations
Cites methods from "Phase I Evaluation of Sequential Do..."
...The regimen consisted of doxorubicin (50 mg/m(2)) and gemcitabine (2000 mg/m(2)) every 2 weeks with growth factor support and was modeled after a highly effective and well tolerated regimen used to treat patients with advanced bladder carcinoma.(15) Based on this experience, we elected to use this regimen to treat patients with sarcomatoid RCC, and well as patients with rapidly progressive RCC of other histologies who may have progressed after immunotherapy...
[...]
140 citations
94 citations
Cites background or methods from "Phase I Evaluation of Sequential Do..."
...The patient received a dose-intense regimen of doxorubicin, 50 mg/m(2) (Day 1), and gemcitabine, 2000 mg/m(2) (Day 1), (AG) every other week with granulocyte– colony-stimulating factor (GCSF) support.(6) After the first cycle of chemotherapy, the left supraclaviclular and base of neck lymphadenopathy were found to have significantly decreased in size on physical examination and the patient’s left arm paresthesias resolved....
[...]
...Based on recent data using an active regimen comprised of AG alternating with ifosfamide, paclitaxel, and cisplatin (ITP) in patients with TCC, we elected to treat our patient with ifosfamide, 1500 mg/m(2) (Days 1–3); paclitaxel, 175 mg/m(2) (Day 1); and cisplatin, 35 mg/m(2) (Days 1–2), every 4 weeks with GCSF support.(6) The patient received two cycles of ITP and developed lower back and left hip pain....
[...]
...Phase I data suggest that regimens combining doxorubicin and gemcitabine (AG) and those combining ifosfamide, paclitaxel, and cisplatin (ITP) are well tolerated, active regimens.(6) A recent Phase II trial of 21 patients with TCC who were treated with sequential AG followed by ITP reported that a major response (either complete response or partial response) was achieved in 18 patients (86%)....
[...]
80 citations
References
871 citations
614 citations
604 citations
572 citations
486 citations